| pubmed-article:12472594 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C1257751 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C0014819 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C0015264 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:12472594 | lifeskim:mentions | umls-concept:C1512045 | lld:lifeskim |
| pubmed-article:12472594 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:12472594 | pubmed:dateCreated | 2002-12-10 | lld:pubmed |
| pubmed-article:12472594 | pubmed:abstractText | Hydroxyurea (HU) has been shown to increase the proportion of fetal haemoglobin (HbF) in most sickle cell patients. A low-dosage regimen increased total haemoglobin (Hb) levels in some thalassaemia intermedia patients by preferentially increasing beta-globin biosynthesis. To further characterize these apparent dose-dependent effects of HU, we examined erythroid cells exposed to HU (5-100 micro mol/l) in two-phase liquid culture. Low doses (from 5 to 25 micro mol/l) increased Hb levels by up to 2.7-fold, and a high dose (100 micro mol/l) increased Hb levels when added at d 3-6 of phase II, with no significant changes in response to HU during the late stage of phase II culture (> or = 9 d). HU exposure during d 0-3 of phase II culture increased the number of erythroid colonies to a maximum of fivefold at 5 micro mol/l HU. GATA-1 mRNA was downregulated at a high dose and GATA-2 was dose dependently upregulated over a lower dosage range. Treatment with 100 micro mol/l HU dramatically upregulated the death receptor DR-5, caspase 3, as determined by cDNA microarray analysis. In contrast, 10 micro mol/l HU modestly upregulated mRNA levels of the early growth response gene. Our results suggest that HU exerts concentration-dependent effects on HbF production and erythropoiesis and that these two effects are mediated by distinct molecular mechanisms. | lld:pubmed |
| pubmed-article:12472594 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12472594 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12472594 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12472594 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:12472594 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:WebbS LSL | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:RodgersGriffi... | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:FibachEitanE | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:TangDelia CDC | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:LiuWenliW | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:ChinKyungK | lld:pubmed |
| pubmed-article:12472594 | pubmed:author | pubmed-author:ZhuJianqion... | lld:pubmed |
| pubmed-article:12472594 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12472594 | pubmed:volume | 119 | lld:pubmed |
| pubmed-article:12472594 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12472594 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12472594 | pubmed:pagination | 1098-105 | lld:pubmed |
| pubmed-article:12472594 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:meshHeading | pubmed-meshheading:12472594... | lld:pubmed |
| pubmed-article:12472594 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12472594 | pubmed:articleTitle | Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways. | lld:pubmed |
| pubmed-article:12472594 | pubmed:affiliation | The Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:12472594 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12472594 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12472594 | lld:pubmed |
